Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 52 of 52 entries
View as:
Phase: N/A
Priority: Normal
Start: 11/30/05
End: 06/30/07
Due: 06/30/08
Phase: N/A
Priority: Normal
Start: 01/31/14
End: 01/31/14
Due: 01/31/15
| Title | NCT ID | Organization | User | Status | Start Date | End Date | Reporting Due Date | Last Checked | User Role | Org Created |
|---|---|---|---|---|---|---|---|---|---|---|
| Phase I/II Open-Label, Dose Escalation Study To Determine The Maximum Tolerated Dose And To Evaluate The Safety Profile of Lenalidomide (Revlimid® CC-5013) With Liposomal Doxorubicin In Subjects With Advanced Ovarian and Primary Peritoneal Carcinoma | NCT00179725 | Celgene Corporation | user2@example.com | None | 2005-11-30 | 2007-06-30 | 2008-06-30 | - | - | 2025-07-14 |
| Study to Determine Efficacy and Safety of CC-486 With Nab-Paclitaxel Versus Nab-Paclitaxel in Patients With Chemotherapy naïve Metastatic Melanoma | NCT01933061 | Celgene Corporation | user2@example.com | None | 2014-01-31 | 2014-01-31 | 2015-01-31 | - | - | 2025-07-14 |